Powered by Google Google ÜbersetzerGoogle Übersetzer
Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Latest Press Releases
View all
TimeHeadline
Just nowFranklin Electric Declares Quarterly Dividend of $0.28 Per Share
Just nowFDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
Just nowPeloton’s World-Class Content to Fuel Spotify’s New Fitness Category Globally
Just nowInsurance Expert Dan Simmons of Hastings, MI Explains Michigan No-Fault Auto Insurance for HelloNation
Just nowBioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
Soligenix Inc logo

Soligenix Inc

About

Soligenix Inc (NASDAQ:SNGX) — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 2 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Mar 31 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Mar 26 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Mar 24 2026
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Mar 23 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Community Chat

Ask AI

6ix6ix